Cwm, LLC Acadia Pharmaceuticals Inc Transaction History

Cwm, LLC

  • $23.3 Billion
  • Q3 2024

A detailed history of Cwm, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Cwm, LLC holds 2,248 shares of ACAD stock, worth $38,373. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,248
Previous 2,112 6.44%
Holding current value
$38,373
Previous $34,000 2.94%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024
BUY
$15.14 - $19.14 $2,059 - $2,603
136 Added 6.44%
2,248 $35,000
Q2 2024

Jul 09, 2024
BUY
$14.62 - $18.42 $1,403 - $1,768
96 Added 4.76%
2,112 $34,000
Q1 2024

Apr 05, 2024
BUY
$17.79 - $30.86 $426 - $740
24 Added 1.2%
2,016 $37,000
Q4 2023

Feb 01, 2024
SELL
$20.78 - $31.77 $1,475 - $2,255
-71 Reduced 3.44%
1,992 $62,000
Q3 2023

Oct 11, 2023
SELL
$20.84 - $33.47 $3,000 - $4,819
-144 Reduced 6.52%
2,063 $43,000
Q2 2023

Aug 03, 2023
SELL
$17.8 - $25.65 $2,812 - $4,052
-158 Reduced 6.68%
2,207 $53,000
Q1 2023

Apr 28, 2023
BUY
$16.32 - $20.92 $38,107 - $48,848
2,335 Added 7783.33%
2,365 $45,000
Q4 2022

Feb 01, 2023
SELL
$14.2 - $18.63 $880 - $1,155
-62 Reduced 67.39%
30 $0
Q3 2022

Oct 27, 2022
SELL
$14.11 - $18.27 $84 - $109
-6 Reduced 6.12%
92 $2,000
Q2 2022

Jul 28, 2022
BUY
$13.01 - $27.22 $299 - $626
23 Added 30.67%
98 $1,000
Q1 2022

Apr 21, 2022
BUY
$20.94 - $27.5 $900 - $1,182
43 Added 134.38%
75 $2,000
Q4 2021

Jan 31, 2022
BUY
$16.79 - $27.09 $436 - $704
26 Added 433.33%
32 $1,000
Q1 2019

Apr 22, 2019
BUY
$16.17 - $27.38 $97 - $164
6 New
6 $0

Others Institutions Holding ACAD

# of Institutions
279
Shares Held
156M
Call Options Held
901K
Put Options Held
314K
View Full List

About ACADIA PHARMACEUTICALS INC

ACAD Quotes by TradingView
  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email